Professional
Added to YB: 2024-05-10
Pitch date: 2024-03-31
VKTX [bullish]
Viking Therapeutics, Inc.
-54.76%
current return
Author Info
No bio for this author
Company Info
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
Market Cap
$4.4B
Pitch Price
$81.97
Price Target
N/A
Dividend
N/A
EV/EBITDA
-13.51
P/E
-18.45
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Baron Global Advantage Fund New Portfolio Holding: Viking Therapeutics, Inc.
VKTX: Developing GLP-1/GIP combo for diabetes, obesity & fatty liver; potentially more effective than $LLY's Mounjaro. 2nd drug targets massive MASH market. Riding new pharma trend of large volume primary care drugs vs high-price rare disease. Obesity alone a $100B+ opportunity in US at just $200/yr pricing (vs current levels) for 1/3 of population.
Read full article (1 min)